Document is current
Any future updates will be listed below
-
Authors
Perluk, Tal Moshe
Friedman Regev, Inbal
Freund, Ophir
Kleinhendler, Eyal
Hershko, Tzlil
Ben-Ami, Sharona
Bar-Shai, Amir
Unterman, Avraham
- License Information
-
More Information
Article History
Received: 24 July 2022
Accepted: 21 December 2022
First Online: 27 December 2022
Declarations
:
: This study was approved and reviewed by the Tel Aviv Sourasky Medical Center (TASMC) ethics committee (approval number 0287-21) and was conducted in accordance with the declaration of Helsinki. This retrospective study did not require individual patient consent as indicated by the TASMC ethics committee approval referenced above.
: Not applicable.
: A.U. reports receiving research funding from Boehringer Ingelheim and the Pulmonary Fibrosis Foundation, personal consulting fees from Boehringer Ingelheim, RemedyCell, Augmanity Nano, and 1E Therapeutics in the last 36 months, and equity in RemedyCell, all outside the submitted work. All other authors report no conflict of interest.
